Related Experiment Videos
Microarray analysis reveals genetic pathways modulated by tipifarnib in acute myeloid leukemia.
Mitch Raponi1, Robert T Belly, Judith E Karp
1Veridex, LLC, Johnson and Johnson Company, San Diego, CA 9212, USA. mraponi1@vrxus.jnj.com
BMC Cancer
|August 27, 2004
Summary
Farnesyl protein transferase inhibitors (FTIs) like tipifarnib impact gene expression in acute myeloid leukemia (AML). This study identified key genetic pathways and potential biomarkers for FTI drug activity in AML.
Area of Science:
- Oncology
- Molecular Biology
- Pharmacology
Background:
- Farnesyl protein transferase inhibitors (FTIs) were initially developed to target oncogenic ras.
- Emerging evidence suggests FTIs have broader therapeutic potential beyond ras inhibition.
- Tipifarnib, an FTI, has shown promise in clinical trials for refractory and relapsed acute leukemias.
Purpose of the Study:
- To identify genetic markers regulated by tipifarnib in acute myeloid leukemia (AML).
- To elucidate the biological pathways influenced by tipifarnib in AML.
Main Methods:
- Gene expression profiling using cDNA microarrays on AML cell lines and patient samples.
- Pathway analysis employing the Ingenuity Pathway Analysis tool.
- Validation of gene expression changes using real-time RT-PCR.
Main Results:
- Tipifarnib consistently modulated a common set of genes across AML cell lines and patient samples.
- Affected pathways include cell signaling, cytoskeletal organization, immunity, and apoptosis.
- Apoptotic gene regulation correlated with Annexin V staining in THP-1 cells, but not HL-60 cells.
Conclusions:
- Tipifarnib influences distinct genetic networks and biological pathways in AML.
- These findings provide a foundation for identifying surrogate biomarkers of FTI drug activity.
- Understanding these pathways enhances the potential of FTIs in leukemia treatment.